The Centers for Medicare and Medicaid Services (CMS) has selected 35 participants for its new, voluntary Cell and Gene ...

CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

Thirty-three states, the District of Columbia, and Puerto Rico will participate in CMS’ voluntary Cell and Gene Therapy (CGT) ...

The Centers for Medicare and Medicaid Services has named 33 states, as well as Washington, D.C., and Puerto Rico, as participants in its Cell and Gene Therapy Access Model, which is designed to treat ...

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

"The Cell and Gene Therapy Access Model will increase access to promising therapies that improve the chances of people living longer, healthier lives," CMS Administrator Chiquita Brooks-LaSure ...

The US regulator has launched a new national initiative to help Medicaid programs fund gene therapies for sickle cell disease ...

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.

A total of 33 states, plus the District of Columbia and Puerto Rico, agreed to participate in the U.S. CMS’ voluntary, outcomes-based program aimed at helping state Medicaid programs cover high-priced ...

Company and CMMI agreed to key terms to be offered to State Medicaid Agencies to support access to LYFGENIA™ gene therapy for sickle cell disease States can opt in to an outcomes-based agreement ...

"The Cell and Gene Therapy Access Model will increase access to promising therapies that improve the chances of people living longer, healthier lives," CMS Administrator Chiquita Brooks-LaSure ...